[go: up one dir, main page]

AR054094A1 - Tratamientos de cancer - Google Patents

Tratamientos de cancer

Info

Publication number
AR054094A1
AR054094A1 ARP050104642A ARP050104642A AR054094A1 AR 054094 A1 AR054094 A1 AR 054094A1 AR P050104642 A ARP050104642 A AR P050104642A AR P050104642 A ARP050104642 A AR P050104642A AR 054094 A1 AR054094 A1 AR 054094A1
Authority
AR
Argentina
Prior art keywords
methods
cancer treatments
cancer cells
treatments
bendamustine
Prior art date
Application number
ARP050104642A
Other languages
English (en)
Original Assignee
Cephalon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36588320&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR054094(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Cephalon Inc filed Critical Cephalon Inc
Publication of AR054094A1 publication Critical patent/AR054094A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Se describen métodos y composiciones para tratar cánceres caracterizados por células cancerosas resistentes a la muerte. En general, tales métodos involucran la administracion de una cantidad terapéuticamente efectiva de un compuesto (Bendamustina) que induce la catástrofe mitotica en algunas, preferentemente en la mayoría o en todas, las células cancerosas. Se proveen también métodos para valorar la eficacia de tales tratamientos.
ARP050104642A 2004-11-05 2005-11-04 Tratamientos de cancer AR054094A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US62519304P 2004-11-05 2004-11-05
US66022605P 2005-03-10 2005-03-10

Publications (1)

Publication Number Publication Date
AR054094A1 true AR054094A1 (es) 2007-06-06

Family

ID=36588320

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP050104642A AR054094A1 (es) 2004-11-05 2005-11-04 Tratamientos de cancer

Country Status (12)

Country Link
US (2) US20060128777A1 (es)
EP (1) EP1814544A4 (es)
JP (1) JP2008519047A (es)
CN (1) CN101933923A (es)
AR (1) AR054094A1 (es)
AU (1) AU2005317047A1 (es)
CA (1) CA2585659A1 (es)
CL (1) CL2009001721A1 (es)
MX (1) MX2007005361A (es)
NO (1) NO20072654L (es)
TW (1) TW200621240A (es)
WO (1) WO2006065392A2 (es)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004092115A2 (en) 2003-04-07 2004-10-28 Axys Pharmaceuticals Inc. Hydroxamates as therapeutic agents
US8436190B2 (en) 2005-01-14 2013-05-07 Cephalon, Inc. Bendamustine pharmaceutical compositions
US20090075967A1 (en) * 2007-09-15 2009-03-19 Protia, Llc Deuterium-enriched ceftriaxone
US20090082416A1 (en) * 2007-09-25 2009-03-26 Protia, Llc Deuterium-enriched bendamustine
AR072777A1 (es) 2008-03-26 2010-09-22 Cephalon Inc Formas solidas de clorhidrato de bendamustina
JP5479453B2 (ja) * 2008-04-17 2014-04-23 ザ・ジョンズ・ホプキンス・ユニバーシティ ＯＮ０１９１０．Ｎａは薬剤耐性腫瘍において化学療法剤活性を増強する
JP5670335B2 (ja) * 2008-09-25 2015-02-18 セファロン、インク． ベンダムスチン液体製剤
UA107186C2 (xx) * 2008-12-03 2014-12-10 Тверді форми дозування бендамустину
PL2367542T3 (pl) * 2008-12-03 2014-05-30 Astellas Deutschland Gmbh Doustne formy dawkowania bendamustyny
ES2675620T3 (es) * 2009-02-25 2018-07-11 Softkemo Pharma Corp. Composiciones de ciclopolisacárido y de bendamustina
US8603521B2 (en) 2009-04-17 2013-12-10 Pharmacyclics, Inc. Formulations of histone deacetylase inhibitor and uses thereof
EP2424506A1 (en) * 2009-04-28 2012-03-07 Cephalon, Inc. Oral formulations of bendamustine
WO2010144675A1 (en) 2009-06-10 2010-12-16 Plus Chemicals Sa Polymorphs of bendamustine hcl and processes for preparation thereof
US8389558B2 (en) * 2009-07-20 2013-03-05 Supratek Pharma Inc. Bendamustine amphiphilic anionic compositions
EP2528602B2 (en) 2010-01-28 2020-02-12 Eagle Pharmaceuticals, Inc. Formulations of bendamustine
PL2575784T3 (pl) * 2010-06-02 2019-03-29 Astellas Deutschland Gmbh Doustne postaci dawkowania bendamustyny
JO3659B1 (ar) * 2010-06-02 2020-08-27 Astellas Deutschland Gmbh أشكال جرعات بينداموستين عن طريق الفم وإستخداماته العلاجية
US8383663B2 (en) 2010-07-19 2013-02-26 Supratek Pharma Inc. Bendamustine anionic-catioinic cyclopolysaccharide compositions
TW201306842A (zh) * 2011-06-15 2013-02-16 Exelixis Inc 使用ｐｉ３ｋ／ｍｔｏｒ吡啶並嘧啶酮抑制劑及苯達莫司汀及／或利妥昔單抗治療惡性血液疾病之組合療法
LT2744515T (lt) 2011-08-16 2022-04-25 Morphosys Ag Kombinuota terapija su anti-cd19 antikūnu ir azoto garstyčiomis
CN103917231B (zh) * 2011-09-13 2016-09-28 药品循环有限责任公司 组蛋白脱乙酰酶抑制剂与苯达莫司汀的联合制剂及其用途
ES2613838T3 (es) 2011-09-26 2017-05-26 Fresenius Kabi Oncology Ltd Un procedimiento mejorado para la preparación de hidrocloruro de bendamustina
US9000021B2 (en) 2012-03-20 2015-04-07 Eagle Pharmaceuticals, Inc. Method of treating bendamustine-responsive conditions in patients requiring reduced volumes for administration
RS65177B1 (sr) 2012-03-20 2024-03-29 Eagle Pharmaceuticals Inc Formulacije bendamustina
US8927516B2 (en) * 2012-03-29 2015-01-06 Institute For Cancer Research Combination of DNA repair inhibition with bendamustine or gemcitabine in the treatment of cancer
US10220051B2 (en) 2012-03-29 2019-03-05 Institute For Cancer Research Combination of DNA repair inhibition with bendamustine or gemcitabine in the treatment of cancer
WO2015017812A1 (en) 2013-08-02 2015-02-05 Pharmacyclics, Inc. Methods for the treatment of solid tumors
US20150087681A1 (en) * 2013-09-25 2015-03-26 Pranav Patel Bendamustine HCL Stable Lyophilized Formulations
WO2015048718A2 (en) 2013-09-30 2015-04-02 Institute For Cancer Research D/B/A The Research Institute Of Fox Chase Cancer Center Inhibition of thymine dna glycosylase in the treatment of cancer
AU2015229842B2 (en) 2014-03-13 2020-06-25 Vasilios VOUDOURIS Bendamustine solid dispersions and continuous infusion
WO2017013237A1 (en) 2015-07-23 2017-01-26 Institut Curie Use of a combination of dbait molecule and parp inhibitors to treat cancer
GB201519573D0 (en) 2015-11-05 2015-12-23 King S College London Combination
WO2018162439A1 (en) 2017-03-08 2018-09-13 Onxeo New predictive biomarker for the sensitivity to a treatment of cancer with a dbait molecule
EP3765613A1 (en) 2018-03-13 2021-01-20 Onxeo A dbait molecule against acquired resistance in the treatment of cancer
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
WO2024261243A1 (en) 2023-06-21 2024-12-26 Hemispherian As Combination comprising a deoxycytidine derivative and a parp inhibitor for use in a method of treating hr proficient cancer

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5204335A (en) * 1986-10-31 1993-04-20 Asta Pharma Aktiengesellschaft Ifosfamide lyophilisate and process for its preparation
US5227373A (en) * 1991-10-23 1993-07-13 Bristol-Myers Squibb Co. Lyophilized ifosfamide compositions
PL174494B1 (pl) * 1992-11-13 1998-08-31 Idec Pharma Corp Kompozycja farmaceutyczna do leczenia chłoniaka z limfocytów B i sposób wytwarzania kompozycji farmaceutycznej do leczenia chłoniaka z limfocytów B
US5595721A (en) * 1993-09-16 1997-01-21 Coulter Pharmaceutical, Inc. Radioimmunotherapy of lymphoma using anti-CD20
ES2142409T3 (es) * 1993-10-27 2000-04-16 Upjohn Co Prostaglandina e 1 estabilizada.
US5955504A (en) * 1995-03-13 1999-09-21 Loma Linda University Medical Center Colorectal chemoprotective composition and method of preventing colorectal cancer
DE19529057B4 (de) * 1995-08-08 2007-12-13 Baxter Healthcare S.A. Ifosfamid-Lyophilisat-Zubereitungen
GB9524334D0 (en) * 1995-11-28 1996-01-31 Philips Electronics Nv Mos transistor
US6034256A (en) * 1997-04-21 2000-03-07 G.D. Searle & Co. Substituted benzopyran derivatives for the treatment of inflammation
US20040072889A1 (en) * 1997-04-21 2004-04-15 Pharmacia Corporation Method of using a COX-2 inhibitor and an alkylating-type antineoplastic agent as a combination therapy in the treatment of neoplasia
US6077850A (en) * 1997-04-21 2000-06-20 G.D. Searle & Co. Substituted benzopyran analogs for the treatment of inflammation
ES2255287T3 (es) * 1998-07-09 2006-06-16 Cephalon, Inc. Composiciones para el tratamiento de la leucemia linfocitica cronica.
US5972912A (en) * 1998-12-17 1999-10-26 S.P. Pharmaceuticals Method for lyophilizing ifosfamide
US6569402B1 (en) * 1998-12-18 2003-05-27 Bristol-Myers Squibb Pharma Company Vitronectin receptor antagonist pharmaceuticals
US6380210B1 (en) * 1999-04-02 2002-04-30 Neurogen Corporation Heteroaryl fused aminoalkyl-imidazole derivatives: selective modulators of GABAa receptors
US6545034B1 (en) * 1999-07-23 2003-04-08 The Regents Of The University Of California Use of etodolac for the treatment of chronic lymphocytic leukemia
US20040152672A1 (en) * 2000-08-09 2004-08-05 Carson Dennis A. Indole compounds useful for the treatment of cancer
EP1350792A1 (en) * 2000-12-11 2003-10-08 Takeda Chemical Industries, Ltd. Medicinal compositions improved in solublity in water
PL362172A1 (en) * 2000-12-11 2004-10-18 Takeda Chemical Industries, Ltd. Medicinal compositions having improved absorbability
DE50213462D1 (de) * 2001-10-15 2009-05-28 Hemoteq Ag Beschichtung von stents zur verhinderung von restenose
US6613927B1 (en) * 2002-02-08 2003-09-02 American Pharmaceutical Partners, Inc. Sterile lyophilized ifosfamide and associated methods
PT1501566E (pt) * 2002-05-09 2008-11-13 Hemoteq Ag Produtos médicos que compreendem um revestimento hemocompatível, produção e utilização do mesmo
AU2003258061A1 (en) * 2002-08-02 2004-02-23 Salmedix, Inc. Therapeutic inhibitionof protein kinases in cancer cells
US6966329B2 (en) * 2003-01-27 2005-11-22 Hydraforce, Inc. Proportional pilot-operated flow control valve
DE10304403A1 (de) * 2003-01-28 2004-08-05 Röhm GmbH & Co. KG Verfahren zur Herstellung einer oralen Arzneiform mit unmittelbarem Zerfall und Wirkstofffreisetzung
WO2004074325A2 (en) * 2003-02-14 2004-09-02 Salmedix, Inc Compositions and methods for the detection and treatment of methylthioadenosine phosphorylase deficient cancers

Also Published As

Publication number Publication date
WO2006065392A8 (en) 2007-03-01
WO2006065392A2 (en) 2006-06-22
WO2006065392A3 (en) 2006-12-21
CA2585659A1 (en) 2006-06-22
MX2007005361A (es) 2008-01-11
US20090209606A1 (en) 2009-08-20
NO20072654L (no) 2007-07-25
CN101933923A (zh) 2011-01-05
AU2005317047A1 (en) 2006-06-22
US20060128777A1 (en) 2006-06-15
EP1814544A2 (en) 2007-08-08
JP2008519047A (ja) 2008-06-05
EP1814544A4 (en) 2009-12-02
CL2009001721A1 (es) 2010-02-19
TW200621240A (en) 2006-07-01

Similar Documents

Publication Publication Date Title
AR054094A1 (es) Tratamientos de cancer
UY28287A1 (es) Combinaciones para el tratamiento de enfermedades que impican proliferación, migración o apoptosis celulares de células de mieloma, o angiogénesis
ECSP045407A (es) Benzazoles sustituidos y el uso del mismo como inhibidores de quinasa raf
NO20065368L (no) Terapeutiske blandinger inneholdende minst et pyrrolobenzodiazepinderivat og fludarabin
ECSP088218A (es) Bencimidazoles sustituidos como inhibidores de cinasa
CR8181A (es) Uso de una combinacion de un inhibidor de la cinasa del receptor del factor de crecimiento epidermico y agentes citotoxicos para el tratamiento e inhibicion del cancer
AR048502A1 (es) Sinergia terapeutica de compuestos anti-cancer
ECSP088821A (es) Derivados de tioxantina y su uso como inhibidores de la mpo
AR083957A1 (es) Tratamiento para modular las celulas nk y metodos para tratar malignidad hematologica
AR047841A1 (es) Metodos y composiciones para el tratamiento de transtornos inmunoinflamatorios
SG157365A1 (en) Compositions and methods for treating neoplastic diseases
AR054566A1 (es) Tratamientoombinado de los tumores que expresan el her
PA8680701A1 (es) Derivados de oxindol
CR10566A (es) Compuestos heterociclicos adecuados para el tratamiento de enfermedades relacionadas con nivel elevado de lipidos
CL2008001743A1 (es) Uso de un compuesto derivado de quinazolina para tratar el cancer; uso del compuesto y de otro compuesto antineoplasico; compuestos derivados de quinazolina; y composicion farmaceutica que los comprende.
UY29796A1 (es) Nuevos compuestos para el tratamiento de trastornos neurológicos, psiquiátricos o del dolor
ECSP088676A (es) Pirazolquinolonas como potentes inhibidores de parp
AR056801A1 (es) Terapia combinada anti- proliferativa con determinados agentes quimioterapeuticos basados en platino e inhibidores de egfr o analogos de pirimidina
WO2009032057A3 (en) Method for the selective therapy of disease
GT200600163A (es) Nuevas combinaciones terapeuticas para el tratamiento o la prevencion de la depresion
CL2007001748A1 (es) Compuesto derivado de 2-arilamino-4-aminopirimidinas, inhibidores de la proteina quinasa c-alfa; composiciones farmaceuticas que los contienen; y su uso para tratar o prevenir la diabetes, el cancer, enfermedades cardiovasculares y otras.
CL2007003251A1 (es) Compuestos derivados de 1h-pirazoles sustituidos, inhibidores de reacciones catalizadas por una quinasa; su procedimiento de preparacion; composicion farmaceutica; compuestos intermediarios; uso de los compuestos principales, utiles en el tratamiento del cancer.
UY31325A1 (es) Composiciones y métodos para tratar enfermedades y trastornos inmunologicos e inflamatorios
BRPI0821116A2 (pt) Composto, composição farmacêutica que o contem, uso deste e método para tratar qualquer mamífero afetado por câncer
ES2723778T3 (es) Terapia dirigida a células madre cancerosas y contra cáncer resistente a fármacos

Legal Events

Date Code Title Description
FB Suspension of granting procedure